AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting

Click here to view online. Add this email to your safelist.

14 April 2016

More than 60 presentations featuring 26 potential medicines across four key scientific platforms, including DNA Damage Response (DDR) and Immuno-Oncology (IO)

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.